Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124(11):1598–617.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moles VM, Grafton G. Pulmonary hypertension in heart failure with preserved ejection fraction. Cardiol Clin. 2022;40(4):533–40.

Article  PubMed  Google Scholar 

Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329(10):827–38.

Article  PubMed  Google Scholar 

Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119–26.

Article  PubMed  PubMed Central  Google Scholar 

Inampudi C, Silverman D, Simon MA, Leary PJ, Sharma K, Houston BA, et al. Pulmonary hypertension in the context of heart failure with preserved ejection fraction. Chest. 2021;160(6):2232–46.

Article  PubMed  PubMed Central  Google Scholar 

Vachiéry JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53(1):1801897. https://doi.org/10.1183/13993003.01897-2018. PMID: 30545974; PMCID: PMC6351334.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. https://doi.org/10.1183/13993003.00879-2022. PMID: 36028254.

Article  PubMed  Google Scholar 

Maron BA, Kovacs G, Vaidya A, Bhatt DL, Nishimura RA, Mak S, et al. Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure: JACC review topic of the week. J Am Coll Cardiol. 2020;76(22):2671–81.

Article  PubMed  PubMed Central  Google Scholar 

Omote K, Sorimachi H, Obokata M, Reddy YNV, Verbrugge FH, Omar M, et al. Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. Eur Heart J. 2022;43(36):3417–31.

Article  PubMed  PubMed Central  Google Scholar 

Sera F, Ohtani T, Tamaki S, Yano M, Hayashi T, Nakagawa A, et al. Pulmonary hypertension with a precapillary component in heart failure with preserved ejection fraction. Heart. 2023;109(8):626–33. https://doi.org/10.1136/heartjnl-2022-321565. PMID: 36543519.

Article  PubMed  Google Scholar 

Assad TR, Hemnes AR, Larkin EK, Glazer AM, Xu M, Wells QS, et al. Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol. 2016;68(23):2525–36.

Article  PubMed  PubMed Central  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032.

PubMed  Google Scholar 

Tampakakis E, Shah SJ, Borlaug BA, Leary PJ, Patel HH, Miller WL, et al. Pulmonary effective arterial elastance as a measure of right ventricular afterload and its prognostic value in pulmonary hypertension due to left heart disease. Circ Heart Fail. 2018;11(4):e004436. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004436. PMID: 29643065; PMCID: PMC5901761.

Article  PubMed  PubMed Central  Google Scholar 

Inciardi RM, Abanda M, Shah AM, Cikes M, Claggett B, Skali H, et al. Right ventricular function and pulmonary coupling in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2023;82(6):489–99.

Article  PubMed  Google Scholar 

Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935–44.

Article  PubMed  Google Scholar 

Heywood JT, Jermyn R, Shavelle D, Abraham WT, Bhimaraj A, Bhatt K, et al. Impact of practice-based management of pulmonary artery pressures in 2000 patients implanted with the CardioMEMS sensor. Circulation. 2017;135(16):1509–17.

Article  PubMed  Google Scholar 

Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015;169(3):323–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329(3):214–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benza RL, Raina A, Abraham WT, Adamson PB, Lindenfeld J, Miller AB, et al. Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor. J Heart Lung Transplant. 2015;34(3):329–37.

Article  PubMed  Google Scholar 

Assmus B, Angermann CE, Alkhlout B, Asselbergs FW, Schnupp S, Brugts JJ, et al. Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS-HF study. Eur J Heart Fail. 2022;24(12):2320–30.

Article  CAS  PubMed  Google Scholar 

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.

Article  CAS  PubMed  Google Scholar 

Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) Trial. Circulation. 2015;131(1):34–42.

Article  CAS  PubMed  Google Scholar 

De Denus S, O’Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, et al. Spironolactone metabolites in TOPCAT-new insights into regional variation. N Engl J Med. 2017;376(17):1690–2.

Article  PubMed  PubMed Central  Google Scholar 

Safdar Z, Cho E. Effect of spironolactone use in pulmonary arterial hypertension-analysis from pivotal trial databases. Pulm Circ. 2021;11(4):20458940211045616.

Article  PubMed  PubMed Central  Google Scholar 

Maron BA, Waxman AB, Opotowsky AR, Gillies H, Blair C, Aghamohammadzadeh R, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol. 2013;112(5):720–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu M, Chen LY, Gairhe S, Mazer AJ, Anderson SA, Nelson JNH, et al. Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model. Am J Physiol Lung Cell Mol Physiol. 2022;322(3):L315–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lahm T, Hess E, Barón AE, Maddox TM, Plomondon ME, Choudhary G, et al. Renin-angiotensin-aldosterone system inhibitor use and mortality in pulmonary hypertension: insights from the veterans affairs clinical assessment reporting and tracking database. Chest. 2021;159(4):1586–97.

Article  CAS  PubMed  Google Scholar 

Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.

Article  CAS  PubMed  Google Scholar 

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.

Article  CAS  PubMed  Google Scholar 

Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.

Article  CAS  PubMed  Google Scholar 

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.

Article  CAS  PubMed  Google Scholar 

Solomon SD, Vaduganathan MBLC, Packer M, Zile M, Swedberg K, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352–61.

Article  PubMed  Google Scholar 

Clements RT, Vang A, Fernandez-Nicolas A, Kue NR, Mancini TJ, Morrison AR, et al. Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril/valsartan. Circ Heart Fail. 2019;12(11):e005819.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaumais MC, Djessas MRA, Thuillet R, Cumont A, Tu L, Hebert G, et al. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovasc Res. 2021;117(5):1391–401.

Article  CAS  PubMed  Google Scholar 

Zhang J, Du L, Qin X, Guo X. Effect of sacubitril/valsartan on the right ventricular function and pulmonary hypertension in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of observational studies. J Am Heart Assoc